Growing and Preserving Innovation in America Act of 2025
Summary
HR1062, introduced Feb 2025, would permanently lock in higher FDII/GILTI tax deductions for US corporations, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This is a direct net-income booster for US multinationals with large international IP revenue streams. The bill is in early committee stage; market impact is structural but delayed pending passage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1062 prevents a 2026 tax increase on US companies' foreign IP income, directly improving after-tax net income for major tech, pharma, and consumer multinationals
- 2.Bill is in early stage (referred to committee Feb 2025) — no imminent passage; structural impact is conditional on full legislative process
- 3.No direct spending; pure tax code preservation — estimated annual benefit ranges from $150M (KO) to $2B (MSFT) per company
- 4.Recent stock price strength in GOOGL, NVDA, AMZN, INTC reflects broader market trends, not bill-driven catalysts yet
Market Implications
The primary implication is that HR1062's passage would structurally increase after-tax earnings for all major US multinationals with significant foreign IP income. Microsoft ($429.25), Alphabet ($349.78), and Apple ($270.71) are the largest beneficiaries by absolute dollar impact due to their massive foreign revenue bases. NVIDIA ($213.17, +5.27% 7-day) and Intel ($84.52, +29.49% 7-day) have stronger momentum but would see smaller absolute tax benefits. Consumer staples PG ($149.17, +4.42% 7-day) and KO ($78.35, +4.98% 7-day) also benefit from their global brand IP structures. The market has not yet priced in this bill's probability given its early stage — any committee advancement would trigger incremental positive price discovery in these names.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Future of Artificial Intelligence Innovation Act of 2026
To amend the Distance Learning and Telemedicine Grants Program to expand eligibility for financial assistance to include the construction and enhancement of facilities and technological systems aimed at delivering telemedicine services, strengthening cybersecurity infrastructure, and supporting distance learning initiatives, including digital literacy, workforce development, and job training, in rural communities.
STOP CSAM Act of 2025
FOUR POINTS TECHNOLOGY, L.L.C.: $150M Social Security Administration Contract
LINC VA Act
MAPWaters Act of 2025
National Programmable Cloud Laboratories Network Act of 2025
Lowering Drug Costs for American Families Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.